title: Aztreonam for inhalation solution, challenges to drug approval and integration into CF care.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA, USA; Division of Pulmonary Medicine, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA. Electronic address: goss@u.washington.edu.
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Goss
authors.affiliation: Adult Cystic Fibrosis Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, 4032, Australia; Queensland Children's Medical Research Institute, Royals Children's Hospital, Herston, 4006, Australia; School of Medicine, University of Queensland, The Prince Charles Hospital, Chermside, 4032, Australia.
authors.forename: Scott C
authors.initials: SC
authors.lastname: Bell
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001398:Aztreonam / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000382:microbiology*; D005260:Female; D006801:Humans; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D001398:Aztreonam; D014031:Tobramycin